UPC issues first decision on second medical use

Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unified Patent Court

Does the UPC offer a fresh take on patent validity?

5 September 2024 A distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF.

Unified Patent Court

Sanofi and Regeneron triumph in UPC decision against Amgen

16 July 2024 UPC’s Munich Central Division revokes Amgen's patent | Decision stems from a revocation action initiated by Sanofi last year | Court's ruling focused on interpretations of patent claims and principles of inventive step.

More features

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Data and delivery: Inside AI's inventorship dilemma

Weil continues expansion with top trade secrets litigator

Top pharma, biotech, and medtech experts gather at LSPN Fall

Mitsubishi Tanabe doubles down on Radicava protection

‘All it takes is a post on Truth Social’: Is this patent reform's moment?

UPC issues first decision on second medical use

More on this story

Editor's picks

Editor's picks

More features